[PDF][PDF] Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Q Wang, Y Zhang, L Wu, S Niu, C Song, Z Zhang, G Lu… - Cell, 2020 - cell.com
Q Wang, Y Zhang, L Wu, S Niu, C Song, Z Zhang, G Lu, C Qiao, Y Hu, KY Yuen, Q Wang…
Cell, 2020cell.com
The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused
significant public health concerns. Recently, ACE2 was reported as an entry receptor for
SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of
SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2),
which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV.
However, atomic details at the binding interface demonstrate that key residue substitutions …
Summary
The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.
cell.com